MIDD0301 sodium  (Synonyms: GL-II-93 sodium)

MIDD0301 (GL-II-93) is an orally available, active γ-aminobutyric acid type A receptor (GABA_AR) inhibitor and anti-asthmatic agent. MIDD0301 exhibits biological and immunotoxicological safety in mice and does not affect the number of circulating lymphocytes, monocytes, and granulocytes. MIDD0301 has no significant adverse immune response at repeated doses, which is better than Prednisone (HY-B0214). MIDD0301 relaxes histamine-contracted guinea pig and human airway smooth muscle and is used in the study of bronchoconstrictive diseases^[1][2].

GABA_AR^[1]

436.21

C₁₉H₁₂BrFN₃NaO₂

2593569-36-7

O=C(C1=C2N(C=N1)C3=CC=C(Br)C=C3C(C4=C(C=CC=C4)F)=N[C@@H]2C)O[Na]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yocum GT, et al. A novel GABAA receptor ligand MIDD0301 with limited blood-brain barrier penetration relaxes airway smooth muscle ex vivo and in vivo. Am J Physiol Lung Cell Mol Physiol. 2019 Feb 1;316(2):L385-L390.  [Content Brief]

  [2]. Zahn NM, et al. MIDD0301 - A first-in-class anti-inflammatory asthma drug targets GABAA receptors without causing systemic immune suppression. Basic Clin Pharmacol Toxicol. 2019 Jul;125(1):75-84.  [Content Brief]